/PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's...
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
USA News Group – With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there’s plenty of anticipation for updates on some of the biggest...
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected...
Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate...
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...